Skip to main content

Pyrosequencing to Hold General Meeting in Sept. on Personal Chemistry Question

NEW YORK, Aug. 22 (GenomeWeb News) - Pyrosequencing's board called today for a general meeting to be held Sept. 25 to decide on the issuing of over 23 million shares of stock in the newly acquired Personal Chemistry.

 

Uppsala, Sweden-based Pyrosequencing announced on Aug. 7 that it had agreed to buy 94.1 percent of Personal Chemistry's shares and to purchase the remaining shares through a separate agreement with the holders of options in Personal Chemistry (see article). Personal Chemistry is also based in Sweden.

 

At the meeting, Pyrosequencing's board will propose that the company issue a maximum of 23.2 million ordinary shares, debentures with a maximum of 11.5 million warrants, and an authorization for the board to issue additional shares and debentures with warrants to remaining stockholders in the future.

 

Once the merger is finalized, Personal Chemistry's shareholders will control 40 percent of the share capital and votes in Pyrosequencing.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.